Antiretroviral therapy and the lipodystrophy syndrome.
'Lipodystrophy syndrome' in the setting of HIV infection has come to encompass a collection of morphological and metabolic abnormalities linked with the use of antiretroviral therapy and other risk factors. We review the clinical literature on this subject as it has evolved historically, taking pertinent methodological issues into account.
John
M
M
Nolan
D
D
Mallal
S
S
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D012307:Risk Factors
D017320:HIV Protease Inhibitors